Gov. Tate Reeves signed bipartisan legislation directing the state to explore clinical trials for ibogaine, a psychedelic compound being studied for its potential to treat addiction, depression, and traumatic brain injury. The bill authorizes the Mississippi State Department of Health to establish a research partnership, with lawmakers signaling that up to $5 million in opioid settlement funds could be allocated in future budget decisions. The move reflects growing state-level interest in alternative treatments, even as ibogaine remains federally classified as a Schedule I substance due to safety concerns.
The article presents both advocacy and skepticism surrounding the effort. W. Bryan Hubbard is highlighted as a key national figure promoting ibogaine research across multiple states, while supporters point to emerging studies suggesting potential benefits for neurological and mental health conditions. At the same time, critics emphasize the limited clinical evidence, safety risks, and the effectiveness of existing approved treatments. The legislation represents an early but notable step in Mississippi’s consideration of ibogaine, with funding and implementation still dependent on future policy decisions.